MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
MURA Mural Oncology
- 3.180
- +0.040+1.27%
Close Dec 20 16:00 ET
- 3.160
- -0.020-0.63%
Post 20:01 ET
54.25MMarket Cap-0.35P/E (TTM)
3.300High3.100Low207.56KVolume3.300Open3.140Pre Close660.96KTurnover1.64%Turnover RatioLossP/E (Static)17.06MShares6.25052wk High0.31P/B40.37MFloat Cap2.87052wk Low--Dividend TTM12.69MShs Float57.200Historical High--Div YieldTTM6.37%Amplitude2.870Historical Low3.184Avg Price1Lot Size
About Mural Oncology Company
Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.
Company Profile
SymbolMURA
Company NameMural Oncology
Listing DateNov 6, 2023
Founded2017
CEODr. Caroline Loew, PhD
MarketNASDAQ
Employees117
Fiscal Year Ends12-31
Address10 Earlsfort Terrace
CityDublin
ProvinceDublin
CountryIreland
Zip Code2
Phone353-1-905-8020
Websitehttp://www.muraloncology.com
Company Executives
- Name
- Position
- Salary
- Dr. Caroline Loew, PhD
- Chief Executive Officer and Director
- 2.52M
- Maiken Keson-Brookes
- Chief Legal Officer
- --
- Adam D. Cutler
- Chief Financial Officer and Principal Accounting Officer
- 743.18K
- Vicki L. Goodman
- Chief Medical Officer
- 705.58K
- Scott T. Jackson, M.B.A.
- Chairman of the Board
- 65.97K
- Dr. George S. Golumbeski, PhD
- Independent Director
- --
- Sachiyo Minegishi, M.B.A.
- Independent Director
- --
- Benjamin J. Hickey, M.B.A.
- Independent Director
- 51.79K
- Dr. Francis M. Cuss, F.R.C.P.,M.B.
- Independent Director
- 58.63K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.